Coston McIsaac & Partners’s Idexx Laboratories IDXX Stock Holding History

Coston McIsaac & Partners’s Portfolio IDXX Stock Details IDXX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$17K	Hold	34	–	–	﹤0.01%	509
2026 Q1	$19K	Buy	34 +1	+3%	+$641	﹤0.01%	473
2025 Q4	$22K	Buy	33 +1	+3%	+$681	0.01%	447
2025 Q3	$20K	Hold	32	–	–	﹤0.01%	446
2025 Q2	$17K	Hold	32	–	–	﹤0.01%	453
2025 Q1	$13K	Buy	32 +1	+3%	+$434	﹤0.01%	463
2024 Q4	$12K	Hold	31	–	–	﹤0.01%	461
2024 Q3	$15K	Hold	31	–	–	﹤0.01%	439
2024 Q2	$15K	Hold	31	–	–	﹤0.01%	417
2024 Q1	$16K	Hold	31	–	–	0.01%	411
2023 Q4	$17K	Hold	31	–	–	0.01%	403
2023 Q3	$13K	Buy	31 +30	+3,000%	+$15K	﹤0.01%	442
2023 Q2	$0	Buy	+1	New	+$479	﹤0.01%	796

Other funds holding IDXX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BAMCO Inc New York $66.6B AUM 7.35% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Coston McIsaac & Partners's IDXX Position: Q2 2026 in Review

Coston McIsaac & Partners held its Idexx Laboratories (IDXX) position steady in Q2 2026 at 34 shares worth $17K. The position accounts for ﹤0.01% of the portfolio, ranked #509.

Coston McIsaac & Partners first reported a position in IDXX in Q2 2023 and has held it in 13 quarters since. The position peaked at $22K in Q4 2025. 1,305 funds tracked by Wall St. Rank hold IDXX as of Q2 2026.

Coston McIsaac & Partners held 34 shares of Idexx Laboratories worth $17K as of Q2 2026.
Coston McIsaac & Partners left its Idexx Laboratories share count unchanged in Q2 2026.
Idexx Laboratories made up ﹤0.01% of Coston McIsaac & Partners's portfolio in Q2 2026, its #509 holding.
Coston McIsaac & Partners first reported a position in Idexx Laboratories in Q2 2023 and has held it in 13 quarters since.
Coston McIsaac & Partners's Idexx Laboratories position peaked at $22K in Q4 2025.
1,305 funds tracked by Wall St. Rank held Idexx Laboratories as of Q2 2026.

Based on Coston McIsaac & Partners's 13F filing for Q2 2026, filed 12 Aug 2026.